In this scenario, tremelimumab, a fully human anti-CTLA-4 IgG2 monoclonal antibody was the first immune checkpoint blocker to be tested in advanced HCC in a 21-patient cohort of advanced, HCV-associated HCC patients as reported by Sangro et al. [53]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.